top of page
VERDI's personalized peptide vaccines induce predicted T cell responses against signet ring cell carcinoma
Personalized VERDI vaccines, developed by the VERDI System (Vaccine Epitopes Ranked by Digital Intelligence), have been demonstrated to induce tumor-specific T-cell responses and extend survival in a patient with advanced gastric cancer.
Personalized Immune Activation
Our technology enables the prediction of T cell-activating epitopes at the individual level, ensuring that VERDI vaccines effectively stimulate patient-specific immune responses.
Importance of Antigen Expression
Quantifying antigen expression in the tumor is crucial to predict the efficacy of VERDI vaccines, increasing the likelihood of tumor eradication.
HLA Allele Expression and Immune Response
HLA allele expression directly impacts antigen presentation and the ability of VERDI vaccines to stimulate effective immune responses.
Real World Evidence for the Efficacy of Personalized Peptide Vaccines
Documenting the successful treatment of patients with personalized peptide vaccines under the “Heilversuch” exemption.
Personalized vaccine may benefit patients with pancreatic cancer
A personalized vaccine was given to patients with pancreatic cancer after surgery, alongside an immunotherapy drug and chemotherapy, and it successfully activated immune cells in half of the patients, potentially delaying the return of the cancer.
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Personalized vaccine treatment of patients with renal cell carcinoma following surgical resection achieved 100% recurrence-free survival at three years with minimal toxicity. Notably, concurrent administration of immune checkpoint inhibitors did not improve vaccine immunogenicity and efficacy.
Driver mutations targeted personalized peptide vaccines
Post-surgery is ideal for personalized vaccine treatment to reduce residual tumor burden and mitigate cancer-mediated immunosuppression.
Immunogenic personal vaccine for patients with melanoma
Durable T Cell responses induced by a personalized peptide vaccine combined with Poly-ICLC (Hiltonol®) in patients with melanoma
Polyclonal origins of colorectal cancer
This study suggests that mutation-driven approaches miss many clonal lineages, reinforcing VERDI’s vaccine strategy targeting multiple tumor-specific antigens.
Individuelle Heilversuche
The overview on the status of individual healing attempts:
Austria
Germany
Switzerland
Relevant Publications
The following publications have been selected for their relevance to the mechanism of action and potential efficacy of our double-personalized peptide vaccine. These studies provide a scientific foundation for understanding how VERDI vaccine may effectively target and eradicate tumor cells.
Tumor Heterogeneity and Targeted Vaccines
This study discusses the need for developing multiple VERDI vaccines targeting diverse antigens to address tumor heterogeneity.
bottom of page